## **Core Concept**
The question revolves around the management of a patient with AIDS (Acquired Immunodeficiency Syndrome) and a low CD4 cell count, who has developed an invasive pulmonary disease due to *Mycobacterium avium* complex (MAC). MAC infections are opportunistic infections that primarily affect individuals with severely compromised immune systems, such as those with advanced HIV infection.

## **Why the Correct Answer is Right**
The optimal management of MAC infections in patients with AIDS involves the initiation of antiretroviral therapy (ART) to boost the immune system and the use of specific antimicrobial therapy against MAC. The correct approach typically includes a combination of **clarithromycin** (or azithromycin) and **ethambutol**, with or without **rifampin**, as part of the treatment regimen. This combination is aimed at controlling the infection and alleviating symptoms. In patients with a CD4 count below 100 cells/μL, prophylaxis against MAC is also considered.

## **Why Each Wrong Option is Incorrect**
- **Option A:** This option might suggest a treatment that is not comprehensive or is incorrect for MAC, such as using only one drug or drugs not typically used for MAC.
- **Option B:** Similarly, this might propose an incomplete or inappropriate regimen, such as omitting key drugs used in MAC treatment or suggesting drugs not commonly used.
- **Option D:** This option could suggest a management plan that does not adequately address the MAC infection or the patient's overall condition, such as focusing solely on symptoms without addressing the underlying infection.

## **Clinical Pearl / High-Yield Fact**
A crucial point to remember is that in patients with HIV/AIDS and a CD4 count below 50 cells/μL, **prophylaxis against MAC** is recommended to prevent the development of MAC disease. The preferred regimen for prophylaxis is **azithromycin** 1,200 mg weekly. Early initiation of **ART** is also critical in managing HIV and related opportunistic infections, including MAC.

## **Correct Answer:** C.